High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma – Results of a comprehensive meta-analysis

Alexander Greb(University of Cologne), Andreas Engert(University of Cologne), Gino Santini(Ospedale Policlinico San Martino), Nöel Milpied(Hôpital Cardiologique du Haut-Lévêque), Hanneke C. Kluin‐Nelemans(University Medical Center Groningen), Sven Trelle(Institute of Social and Preventive Medicine), Daniel Schiefer, Umberto Vitolo(Candiolo Cancer Institute), Ulrich Kaiser(University of Applied Sciences Landshut), Tanin Intragumtornchai(Chulalongkorn University), Cármino Antônio De Souza(Universidade Estadual de Campinas (UNICAMP)), Guido Schwarzer(University Medical Center Freiburg), Julia Bohlius(University of Bern), Christian Gisselbrecht(Institut Universitaire de France), Maurizio Martelli(University of Milan), Leo F. Verdonck(Isala)
Cancer Treatment Reviews
April 3, 2007
10.1016/j.ctrv.2007.02.002
Cited by 86

Related Papers

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
|The Lancet|2007|1.4k
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
|Blood|2007|971
<b>netmeta</b>: An <i>R</i> Package for Network Meta-Analysis Using Frequentist Methods
|Journal of Statistical Software|2023|451